To the Editor:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
To the Editor:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Jason Tye-Din is a co-inventor of patents pertaining to the use of gluten peptides in therapeutics, diagnostics and non-toxic gluten; a shareholder of Nexpep; and consultant to ImmusanT. A James Daveson has performed clinical trials for ImmusanT.